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Osteogenesis imperfecta (OI) is a heritable disorder that ranges in severity from death in the perinatal period to an increased lifetime risk
of fracture. Mutations in COL1A1 and COL1A2, which encode the chains of type I procollagen, result in dominant forms of OI, and
mutations in several other genes result in recessive forms of OI. Here, we describe four recessive-OI-affected families in which we iden-
tified causative mutations in wingless-type MMTV integration site family 1 (WNT1). In family 1, we identified a homozygous missense
mutation by exome sequencing. In family 2, we identified a homozygous nonsense mutation predicted to produce truncated WNT1. In
family 3, we found a nonsense mutation and a single-nucleotide duplication on different alleles, and in family 4, we found a homozy-
gous 14 bp deletion. The mutations in families 3 and 4 are predicted to result in nonsense-mediated mRNA decay and the absence of
WNT1. WNT1 is a secreted signaling protein that binds the frizzled receptor (FZD) and the coreceptor low-density lipoprotein-
receptor-related protein 5 (LRP5). Biallelic loss-of-function mutations in LRP5 result in recessive osteoporosis-pseudoglioma syndrome
with low bone mass, whereas heterozygous gain-of-function mutations result in van Buchem disease with elevated bone density.
Biallelic loss-of-function mutations in WNT1 result in a recessive clinical picture that includes bone fragility with a moderately severe
and progressive presentation that is not easily distinguished from dominant OI type III.In most populations, more than 95% of individuals with
osteogenesis imperfecta (OI [MIM 166200, 166210,
259420, and 166220]) have dominant mutations in the
type I collagen genes, COL1A1 (MIM 120150) and
COL1A2 (MIM 120160). Recessively inherited forms of OI
(MIM 613849, 610682, 610915, 259440, 613848,
610968, 613982, 614856, and 615066) account for most
of the remainder. These phenotypes can result from muta-
tions in (1) genes important for osteoblast differentiation
(SP71 [MIM 606633]), (2) genes encoding proteins that
modify collagens or act as chaperones during assembly
and secretion of collagens (CRTAP2,3 [MIM 605497],
LEPRE14,5 [MIM 610339], PPIB6–8 [MIM 123841],
SERPINH19 [MIM 600943], FKBP1010,11 [MIM 607063],
SERPINF112,13 [MIM 172860], and BMP114,15 [MIM
112264]), or (3) genes that modulate intracellular calcium
levels (TMEM38B16 [MIM 611236]). Most laboratories
that study OI have seen affected families in which the
molecular basis remains unsolved. We used exome
sequence analysis17 to identify a homozygous WNT1
mutation in one family and then screened 37 additional
probands with moderate to lethal OI (mutations in
COL1A1, COL1A2, and other genes previously linked to
recessive forms of OI had previously been excluded, and
these individuals had normal mobility of type I collagen
as detected by polyacrylamide-gel electrophoresis). All
samples were collected according to the guidelines of1Department of Pathology, University of Washington, Seattle, WA 98195-7470
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and proper informed consent was obtained. Among the
37 additional probands, we identified three families
affected by biallelic WNT1 mutations that led to moder-
ately severe and progressive forms of OI.
Exome sequence analysis was done by the Northwest
Genomics Center at the University of Washington with
DNA from two adult siblings, the proband (IV-2) and the
unaffected sister (IV-4), from family 1 (Figure 1A). In brief,
genomic DNA was extracted from blood and 1 mg was sub-
jected to a series of library-construction steps, including
fragmentation through acoustic sonication (Covaris), end
polishing and A tailing, ligation of sequencing adaptors,
and PCR amplification with 8 bp barcodes for multiplex-
ing. Exome capture was done with the ~36.5 Mb target
from Roche Nimblegen SeqCap EZ v.2.0 (~300,000 exons
and flanking sequence). The barcoded exome libraries
were pooled, and then massively parallel sequencing by
synthesis with fluorescently labeled, reversibly termi-
nating nucleotides was carried out on a HiSeq machine.
The demultiplexed BAM files were aligned to a human
reference (UCSC Genome Browser hg19) with Burrows-
Wheeler Aligner v.0.5.9.18 Read pairs not mapping within
5 2 SDs of the average library size (~125 5 15 bp for
exomes) were removed. Aligned read data were edited by
duplicate removal (i.e., the removal of reads with duplicate
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Figure 1. Pedigrees of the Families
Affected by WNT1 Mutations
Families 1 (A), 2 (B), 3 (C), and 4 (D). For
family 1, exome sequences were deter-
mined for individuals IV-2 and IV-4.
Arrows indicate the proband from each
family, and the asterisks indicate the
individuals studied from each family.realignment was performed (GATK IndelRealigner;
v.1.0-6125), and base qualities were recalibrated (GATK
TableRecalibration; v.1.0-6125). Variant detection and
genotyping were performed with the UnifiedGenotyper
tool from GATK (v.1.0-6125). The SeattleSeq Annotation
Server was used for annotating variants for providing
dbSNP reference SNP IDs, gene names and accession
numbers, the predicted functional effect (e.g., splice-site,
nonsynonymous, missense, etc.), protein positions and
amino acid changes, PolyPhen predictions, conservation
scores (e.g., PhastCons and Genomic Evolutionary Rate
Profiling), the ancestral allele, dbSNP allele frequencies,
and known clinical associations. After this procedure, the
data set for the two adult siblings (IV-2 and IV-4) in family
1 contained approximately 17,000 variants. Removal of
all intergenic and intronic variants, variants present in
dbSNP, or variants represented greater than ten times in
the National Heart, Lung, and Blood Institute (NHLBI)
Exome Sequencing Project Exome Variant Server (EVS)
reduced the list to 2,400. When only variants that were
homozygous in the proband and heterozygous or homo-
zygous at the same site for a different nucleotide were
considered, the number of variants for consideration was
reduced to 17. In the proband, this group consisted of
nine coding synonymous changes, a 14 bp deletion, six
missense changes, and a variant within the 50 UTR ofThe American Journal of Humana gene. None of the coding synony-
mous changes appeared to alter splice
enhancer or suppressor sequences
and were therefore not considered
further. Variants with a low con-
servation score were discarded. The
remaining five candidate genes
were OR4Q3, WNT1 (MIM 164820),
NAV3 (MIM 611629), OTOGL (MIM
614925), and CELA3A. Because
biallelic loss-of-function mutations
in low-density lipoprotein-receptor-
related protein 5 (LRP5 [MIM
603506]), which encodes a coreceptor
of WNT1, result in recessive osteopo-
rosis-pseudoglioma syndrome (OPPG
[MIM 259770]) with low bone mass
and because heterozygous gain-of-
function mutations result in domi-
nantly inherited van Buchem disease,
type 2 (MIM 607636) (also knownas endosteal hyperostosis) with elevated bone density,
WNT1 was the best candidate gene. The proband (IV-2 in
family 1) was homozygous for a missense mutation
(c.893T>G [p.Phe298Cys]) in WNT1 (RefSeq accession
number NM_005430.3), and the unaffected sibling (IV-4)
was homozygous for the wild-type allele.
The proband (IV-2) had her first recognized fracture
(femur) at the age of 2 years after mild trauma when she
started to walk. Radiography at the time revealed a healed
fracture of her humerus, but this had not been noted
clinically. The diagnosis of OI was reached after several
additional fractures and progressive long-bone deformity.
She had blue sclera, her teeth were normal, her hearing
was normal, and her intellectual function was normal
(she was a high school graduate). Studies of dual energy
X-ray absorptiometry were not done. Her younger brother
(IV-3) had fractures that began at the age of 1 year and
developed more severe deformity. He had normal teeth,
normal hearing, and normal intellectual function (he
was a college graduate). His scleral hue was not noted.
Both individuals were treated surgically for the correction
of deformities. Neither was treated with bisphosphonates.
Radiographs taken when the individuals were in their
late 20s showed a dramatic decrease in bone density and
very marked deformity and shortening of long bones
with striking scoliosis (Figure 2A); no other clinicalGenetics 92, 590–597, April 4, 2013 591
Figure 2. Radiographs of Affected Indi-
viduals with WNT1 Mutations
(A) Radiographs taken in the mid 20s of
individual IV-3 in family 1. There is
marked bowing of the long bones in each
extremity, low bone density, and striking
scoliosis of the spine.
(B) Radiographs taken when II-6 (proband)
from family 2 was 18 months of age show
diminished mineralization of all long
bones, bowing of several long bones, very
marked bilateral angulation of the prox-
imal femur, thin ribs, diminished calvarial
mineralization, lack of bone modeling,
and scoliosis.
(C) In radiographs taken of individual II-3
from family 2, the progression of scoliosis
over the first year of life is apparent. There
is marked change in bone structure and an
increase in femoral bowing over 7 years.
(D) At the age of 7 months, individual II-
1 from family 4 has decreased bone miner-
alization, platyspondyly, almost absent
calvarial mineralization, but maintenance
of long-bone structure with the exception
of the fracture in the right radius.information was available. Capillary sequencing (primers
are available upon request) confirmed the exome sequence
analysis in IV-2 and IV-4 and identified the homozygous
c.893T>G mutation in the other affected sibling (IV-3 in
family 1) (Figures 3A and 3B). Parental samples were not
available for analysis.
Family 2 is of Hmong origin, and the proband
(Figure 1B) has a clinical picture of severe OI. Both affected
individuals (II-3 and II-6) are homozygous for a nonsense
mutation (c.884C>A [p.Ser295*]) (Figures 3A and 3B)
within the last exon of WNT1; this mutation results in
stable mRNA (data not shown) and is predicted to result
in a truncated protein. The same mutation has been
identified in another Hmong family by an independent
group and will be reported (Brendan Lee, personal com-
munication). The father (I-1) and mother (I-2) are carriers
of the mutation. Cultured fibroblasts from the proband
(II-6) synthesized and secreted type I procollagen normally
(data not shown). Although mRNA could be identified at592 The American Journal of Human Genetics 92, 590–597, April 4, 2013a level similar to that in control fibro-
blasts, WNT1 was not at detectable
levels in cells from either the proband
or a control. As a consequence, we
could not assess protein stability in
cultured dermal fibroblasts.
The proband (II-6) is the sixth child
born to first-cousin parents and is the
second affected child within the sib-
ship. Antenatally, a concern was
raised about a brain malformation.
He had a right humeral fracture at
birth. When he was 14 months of
age, anMRI of his brain revealed rightunilateral cerebellar hypoplasia with congenital absence
of the vermis, pontine hypoplasia, and hypoplasia of the
mesencephalic tectum. The supratentorial anomalies
included a small anterior commissure, hypoplasia of the
optic chiasm and the hypothalamus, and closed-lip schi-
zencephaly in the parasagittal region of the left occipital
lobe. At 17 months of age, the proband was brought to
the Children’s Hospital and Clinics of Minnesota because
of concerns about failure to thrive, developmental delays,
and multiple fractures. At that time, he could hold his
head up but had not met other significant developmental
milestones. The baby was hospitalized for failure to thrive
and was found to have feeding dysfunction that required
a gastrostomy tube.
When he was 18 months old, his length was 75 cm
(Z score ¼ 2), his weight was 8.06 kg (Z score ¼ 3.46),
and his head circumference was 45.5 cm (fifth percentile).
He was nondysmorphic in appearance, had normal teeth,
and had normal scleral hue. The right humerus and both
Figure 3. WNT1 Mutations in Each Family
(A) Exon-intron structure and mutations in WNT1 in four families. Color coding is as follows: purple, family 1; red, family 2; black,
family 3; and blue, family 4.
(B) Sequence images of mutations in each family. Chromatograms labeled with N represent the normal reference sequence.femurs were bowed (Figure 2B). He did not visually track
or engage with the mother. Laboratory results within
the reference range included creatine kinase, calcium,
albumin, total serum protein, vitamin D, alkaline phos-
phatase, alanine transaminase, aspartate transaminase,
free T4, thyroid-stimulating hormone, and parathyroid
hormone. A skeletal survey showed several lambdoid intra-
sutural bones. There were multiple flattened vertebralThe Ambodies throughout the thoracic and upper lumbar spine.
There weremultiple fractures noted within the extremities,
bowing at sites of healing, and areas of periosteal reaction.
The healing fractures of both femoral diaphyses were
associated with conspicuous apex anterior bowing.
The older affected brother (II-3) was born at 38 weeks of
gestation and is the third child born to his healthy parents.
At 3 hr of age, he was recognized to have a transverseerican Journal of Human Genetics 92, 590–597, April 4, 2013 593
fracture of his left humerus, and at 10 days of age, he had
a fracture of his right humerus. The first skeletal survey was
taken when he was 2 months old and showed multiple
extremity fractures, vertebral body compression, wormian
bones, and generalized demineralization. Subsequently,
several fractures occurred with resultant bone deformities.
He has been treated with intermittent pamidronate infu-
sion since he was 2 years old. Radiographs taken when
he was 2 months, 9 months, and 14 months old show
the progression of scoliosis (Figure 2C). He had marked
bowing and deformity of the femurs by age 7 years. Devel-
opmentally, he has significant delays and a diagnosis of
autism. At age 7 years, he had normal scleral hue and
normal vision. He had developed self-injurious behavior,
had no words or verbal skills, and had no way to directly
indicate his needs. An MRI of his brain was normal. He
was unable to walk but did command crawl and rolls easily.
Measures of bone mineral density in both carrier parents
were normal.
The affected individual (II-1) in family 3 (Figure 1C) has
two mutations (c.506dupG [p.Cys170Leufs*6] and
c.259C>T [p.Gln87*]) (Figures 3A and 3B), which were
shown to be on different alleles by allele-specific amplifi-
cation (data not shown). Both are predicted to lead to
unstable mRNAs. The DNA for this study was extracted
from a blood sample obtained when the child was 1 year
and 9 months of age. At that time, there was a history of
multiple fractures, poor feeding, delayed development,
and recurrent infections. He had ptosis, could not hold
his head up, and had a high arched palate. A computed-
tomography scan showed thinning of the left temporal
bone, and the referring physician thought that the child
had a severe form of OI. The X-rays were not available
to us to confirm these findings. Neither fibroblasts from
the proband nor parental samples were available for
study, and the clinical outcome of the child is unknown
at this time.
Family 4 is from an isolated population in Newfound-
land. The proband is homozygous for a deletion leading
to a frameshift and premature termination codon (c.287_
300delAGTTCCGGAATCGC [p.Gln96Profs*54]) (Figures
3A and 3B). The mutation is predicted to result in unstable
mRNA as a result of nonsense-mediated decay and thus
lead to the absence of WNT1. The father (I-1), mother
(I-2), and brother (II-2) are all confirmed carriers.
At the age of 5 weeks, the female proband presented with
a right humeral fracture. Skeletal survey showed multiple
fractures—including those of the left humerus, the right
seventh rib, and three metatarsals—that were thought to
be 2–3 weeks old. There was osteopenia and compression
of several lumbar vertebrae. At the age of 8 months, she
began regular intravenous bisphosphonate infusions but
continued to fracture. When she was 2 years old, intrame-
dullary (IM) nails were placed in both femurs and tibiae.
When she was 3 years and 9 months old, the distal portion
of the left tibial nail erupted through the cortex andbecame
subcutaneous and was replaced by an expansile nail.594 The American Journal of Human Genetics 92, 590–597, April 4, 2When she was 13 months old, a brain MRI showed
a type 1 Chiari malformation with 2 cm of tonsillar
descent, which has been managed conservatively. The
proband was born with right ptosis, which was repaired
when she was 2 years old. When she was 2.5 years old,
her parents became concerned about her development
when they noticed crowd aversion and sound hypersensi-
tivity. She started using single words just after her second
birthday and joined words just before her third birthday.
At 3 years of age, she was diagnosed with autism spectrum
disorder and started receiving applied-behavioral-analysis
therapy at home. By the age of 3 years and 5 months,
she spoke in sentences.
On examination at age 3 years and 5 months, her height
was 84.5 cm (less than the fifth percentile), her weight was
10.9 kg (less than the fifth percentile), and her head
circumference was 48 cm (þ1 SD). She had mild residual
right ptosis and no other dysmorphic facial features. Her
hands and feet were small: total hand length was 9.6 cm,
and total foot length was 12.1 cm (both less than the third
percentile).
WNT proteins are characterized by a set of 22 conserved
cysteine residues that form the intrachain disulfide bridges
that maintain the tertiary protein structure. WNT proteins
are N-glycosylated and are acylated by the addition of
palmitate and/or palmitoleic acid at a single serine residue
(p.Ser224 in WNT1).19 Acylation is required for the intra-
cellular trafficking and full activity of the protein when
secreted.20 Recently, the crystal structure of a complex
including Xenopus Wnt8 (xWnt8) bound to the cysteine-
rich domain (CRD) of the mouse frizzled8 receptor (Fz8)
was determined.19 xWnt8 has a two-domain structure
with ‘‘thumb’’ and ‘‘index-finger’’ extensions that interact
with the Fz8-CRD domain. The carboxy-terminal domain
(CTD) ‘‘index finger’’ has two b sheets maintained by six
disulfide bridges, and the amino-terminal domain (NTD)
‘‘thumb’’ consists of a cluster of a helices stabilized by
five disulfide bridges. The thumb extension at the NTD
contains the palmitoleic acid residue that appears to
interact with the hydrophobic groove of the Fz8 CRD,
and the index-finger extension at the CTD also shows
multiple contacts with hydrophobic regions of Fz8.
Placement of the human WNT1 mutations on this
model provides some insight into the mechanisms
we might expect. The family 2 mutation (c.884C>A
[p.Ser295*]) introduces a stop codon within the last exon
(exon 4). In cultured fibroblasts, we found a stable mRNA
(data not shown). A truncated protein that lacks 11 of 22
conserved cysteine residues and eliminates the entire
CTD of the protein would be encoded by the mRNA. We
could not determine whether the protein would be stable,
but if it would, interaction with hydrophobic domains
of the receptor would be ablated. In family 3 (see Fig-
ure 1C), the affected individual (II-1) is a compound
heterozygote for two mutations (c.506dupG [p.Cys170
Leufs*6] and c.259C>T [p.Gln87*]), and in family 4,
a 14 bp deletion (c.287_300delAGTTCCGGAATCGC013
[p.Gln96Profs*54]) was identified. These mutations are
predicted to generate unstable mRNAs, which would be
targeted for nonsense-mediated decay and result in the
absence of WNT1. The missense mutation in family 1
(c.893T>G [p.Phe298Cys] in the last exon) changes
a phenylalanine residue at position 298 to a cysteine
residue within the CTD of WNT1. In other WNT proteins,
the equivalent 298 position tolerates either a hydrophobic
(phenylalanine) or a polar (tyrosine) amino acid, but in
either case, the adjacent residue is a conserved cysteine.
The change to cysteine at position 298 introduces a tandem
cysteine-cysteine set (of which two occur naturally) into
the protein structure. The other two cysteine sets are also
within the CTD, and the most C-terminal set was shown
to be involved in an unusual tandem disulfide bond.19 It
is not clear what effect a third cysteine set would induce,
but given the highly conserved nature of the cysteine
residues in all WNT proteins, the change is likely to have
a deleterious effect.
The pathway frommutations inWNT1 to the OI pheno-
type is not yet clear. WNT1 interacts with two transmem-
brane receptor proteins, the frizzled receptor (FZD) and
the coreceptor LRP5. Through these interactions, WNT1
regulates the canonical Wnt pathway through the phos-
phorylation of cytoplasmic b-catenin.21,22 Upon interac-
tion of WNT1 with the receptor complex, b-catenin is
released from a degradation complex in the cytoplasm
and translocated to the nucleus, where it interacts with
the transcription factor TCF/LEF, and targeted gene expres-
sion is modulated. SP7 (which encodes a transcription
factor required for osteoblast differentiation and bone
formation) and ALPL (MIM 171760) (which encodes
tissue-nonspecific alkaline phosphatase that is key to
bone mineralization) are among the downstream targets
of Wnt signaling.23,24 A homozygous mutation in SP7
was identified in a child who has an OI type III–IV clinical
picture and who was born into a consanguineous Egyptian
family.1 The mutation is predicted to alter DNA-binding
properties of the encoded protein, osterix, and is thus
thought to affect the expression of the downstream
bone-related genes and osteoblast differentiation. Alter-
ations in WNT1 signaling might thus alter SP7 expression
and result in similar downstream effects.
The canonical Wnt signaling pathway was recognized to
play a role in bone formation and maintenance when
homozygous loss-of-function mutations in LRP5, which
encodes a coreceptor of WNT, were found to cause
OPPG.25 There are no reports of pseudoglioma in any of
our affected individuals. In situ studies have shown that
Lrp5 is expressed in mouse osteoblasts and that the expres-
sion pattern of Lrp5 changes over time in vitro as pluripo-
tent mesenchymal cells are induced by Wnt-mediated
signaling toward differentiation along the osteoblastic
lineage. In addition, WNT-induced LRP5 signaling is
necessary for the induction of alkaline phosphatase,
a marker for mature osteoblasts, which places LRP5
and WNT together in the cell-differentiation pathway.The AmInterestingly, family members heterozygous for the LRP5
loss-of-function mutations were found to have lower
bone mineral density than were the age- and gender-
matched controls.25
In mice homozygous for mutations in both Lrp5 and
Lrp6, documented osteoblast proliferation was defective,
so this pathway is another downstream target of Wnt
signaling. In humans, heterozygous missense (gain-of-
function) mutations in LRP5 result in van Buchem disease
type 2 (endosteal hyperostosis) with elevated bone
density,26,27 and equivalent mutations inmice recapitulate
the human high-bone-mass phenotype.28
In mesenchymal stem cells, Wnt proteins play a role in
sustaining stem cell self-renewal and differentiation
potential,29,30 and there is evidence that Wnt signaling
in osteocytes is required for normal bone homeostasis.31
The studies of mutations in LRP5, outlined above, place
the canonical Wnt pathway in the early stages of bone
development and suggest, in addition, that it has a role
during osteoblast differentiation and proliferation. Given
the tight regulation between osteoblasts and osteoclasts
during skeletal development,32 perhaps both cell types
are downstream targets of Wnt signaling. Wnt1-knockout
mice33 die in the neonatal period with virtually no
midbrain and no cerebellum, whereas the naturally occur-
ring Wnt1 mutant ‘‘swaying’’ mice34 (with c.565delG
[p.Glu189Argfs*10]) live to adulthood and are character-
ized by ataxia and hypertonia, a phenotype attributed to
the malformation of the anterior regions of the cere-
bellum. This mutation is similar to the one that we identi-
fied in family 3. Given that neither mouse model describes
a bone phenotype, insight regarding the effect of altered
WNT1 function on bone development is lacking. The
cerebellar malformations seen in the mouse models were
not seen in our four families affected by human WNT1
mutations, which suggests that either other WNT proteins
or other compensatory pathways are involved in this
process of brain development in humans.
In these four families, biallelic mutations in WNT1 re-
sulted in a moderately severe and progressive OI pheno-
type that is indistinguishable from dominant OI type III.
The WNT1 mutations we identified in 10.5% of our 38
previously unsolved OI cases are not present in the NHLBI
EVS or in dbSNP. As noted above, the mutation identified
in the Hmong family was detected in another family
from the same region by another group. In three of the
families, the affected individuals also have learning and
developmental delays, but we are uncertain of the status
in the fourth family. As a result, it is not yet clear whether
these neurologic abnormalities are part of the clinical
phenotype that results from mutations in WNT1 or
whether they are due to other factors. As more families
are identified, this should become more clear. Although
the precise mechanisms by which mutations in WNT1
result in OI have not yet been defined, these findings
should lead to a more detailed analysis of the role of the
gene product in bone development, stabilization, anderican Journal of Human Genetics 92, 590–597, April 4, 2013 595
structure and might provide another OI subset in which
targeted treatment could be effective.Acknowledgments
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